During and after an exacerbation, mental recovery involves taking care of both your physical and mental health. Resting, ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

and before the pandemic took hold Synairgen was already putting its inhaled version through its paces in trials involving subjects with asthma and chronic obstructive pulmonary disease (COPD).

As wildfires continue to affect communities across California, people not only need to remain vigilant about the threat of ...

Stiolto Respimat (tiotropium bromide/olodaterol) is an inhaled medication for the treatment of chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema. It’s not indicated as a ...

Whether it’s due to environmental pollutants, allergens, or chronic conditions like asthma and COPD, many find themselves struggling ... Unlike conventional medications that often focus solely on ...

COPD treatment goal is to help you breathe easier and help regular activities. Medications along with lifestyle approaches can help. When you have COPD, medications can go a long way to help you ...

Cole Schmidtknecht had chronic asthma since he was a child, and had used a steroid inhaler to control his symptoms for more ...

becoming the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years, and launched a few weeks later. Third-quarter sales of $6 ...